Deciphera Pharmaceuticals, Inc. (DCPH) News

Deciphera Pharmaceuticals, Inc. (DCPH): $12.88

0.37 (-2.79%)

POWR Rating

Component Grades








Add DCPH to Watchlist
Sign Up

Industry: Biotech




#76 of 359

in industry

Filter DCPH News Items

DCPH News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

DCPH News Highlights

  • For DCPH, its 30 day story count is now at 4.
  • Over the past 14 days, the trend for DCPH's stories per day has been choppy and unclear. It has oscillated between 1 and 2.

Latest DCPH News From Around the Web

Below are the latest news stories about DECIPHERA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate DCPH as an investment opportunity.

Deciphera Pharmaceuticals Inc (DCPH): A Deep Dive into Its Performance Potential

Unraveling the Factors That Could Limit Future Growth

Yahoo | September 22, 2023

Deciphera Pharmaceuticals (DCPH): An Intriguing Value Play with a Modestly Undervalued Market ...

Scrutinizing the Intrinsic Value of Deciphera Pharmaceuticals

Yahoo | September 22, 2023

Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., September 15, 2023--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that in connection with the hiring of Dashyant Dhanak, Ph.D., Executive Vice President and Chief Scientific Officer, the Compensation Committee of Deciphera’s Board of Directors approved the grant of a stock option to purchase 65,900 shares of Deci

Yahoo | September 15, 2023

Deciphera Pharmaceuticals, Inc. (DCPH) Down 9.7% Since Last Earnings Report: Can It Rebound?

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 8, 2023

Deciphera Pharmaceuticals (NASDAQ:DCPH) shareholders have endured a 66% loss from investing in the stock three years ago

The truth is that if you invest for long enough, you're going to end up with some losing stocks. But the last three...

Yahoo | August 22, 2023

Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now

Biotech stocks may offer some of the most explosive opportunities on the market.

Ian Cooper on InvestorPlace | August 21, 2023

3 Under-the-Radar Biotech Stocks to Buy in 2023

Most people have either had cancer themselves or know someone who has. According to the American Cancer Society, 1 in 3 people in the U.S. will be diagnosed with one of the numerous forms of cancer. Deciphera Pharmaceuticals (NASDAQ: DCPH), Mirati Therapeutics (NASDAQ: MRTX) and MacroGenics (NASDAQ: MGNX) are lesser-known biotech companies with significant potential since they focus on oncology therapies.

Yahoo | August 19, 2023

Why Shares of Deciphera Pharmaceuticals Rose This Week

Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) were up more than 17% for the week as of Friday at 2 p.m. ET, according to data provided by S&P Global Market Intelligence. All but $1 million of the revenue came from sales of gastrointestinal stromal tumor (GIST) therapy Qinlock. Qinlock is approved as a fourth-line treatment for GIST, a type of stomach cancer.

Yahoo | August 11, 2023

Deciphera (DCPH) Q2 Earnings Beat, Qinlock Drives Revenues

Deciphera (DCPH) reports narrower-than-expected loss for the second quarter of 2023. Qinlock drives year-over-year sales.

Yahoo | August 10, 2023

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 8.06% and 5.42%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 9, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!